SlideShare una empresa de Scribd logo
1 de 17
Standard Of Care Costs in Clinical Trials An Oncology-Focused CRO Perspective Presented by: Donna Beardsworth Founder
Beardsworth  –  An Oncology-Focused CRO ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Therapeutic Area  Expertise: Oncology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Oncology Trial Challenges Today ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SOC Usage ,[object Object],The Importance of Standard of Care Considerations  in Your Company’s Approach to Developing Clinical Grants Very Important 73% Somewhat Important 23% Not Very Important 3% Not At All Important 1% Total 100%
SOC Usage ,[object Object],Reasons for Using SOC to Incorporate SOC Considerations Percent Avoid paying for procedures  covered by third parties 85% Insure paying fair market value by  avoiding possible double payment 83% Assist in protocol design 81%
[object Object],[object Object],[object Object],[object Object],SOC Usage
Impediments to SOC Usage ,[object Object],[object Object],[object Object],[object Object],Why does it work in Oncology?
National Comprehensive Cancer Network ,[object Object],[object Object],[object Object],[object Object]
National Comprehensive Cancer Network ,[object Object],[object Object],[object Object],[object Object],[object Object]
NCCN Guidelines and 3 rd  Party Payers ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Trial Design and Implementation Considerations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Two Oncology Trials Analyzed
SOC Analysis – Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Leukemia Single Patient Duration  36 Months Number of Visits 34 Number of Patients 22 Number of Procedures 42 Number of SOC Procedures 34 Number of Expensive SOC Procedures 2 Total Cost for Procedures Per Patient  before  SOC $52,264 USD Total Cost for Procedures Per Patient  after  SOC  $ 34,662 USD Total SOC Savings Per Patient  $ 17,602 USD Total SOC Savings for All Patients $ 387, 244 USD Total % of SOC Savings  34 %
SOC Analysis –  Ovarian Cancer Single Patient Duration  89 Weeks Number of Visits 163 Number of Patients 360 Number of Procedures 18 Number of SOC Procedures 12 Number of Expensive Procedures 2 Total Cost for Procedures Per Patient  before  SOC  $ 109,423 USD Total Cost for Procedures Per Patient  after  SOC  $91,087 USD Total SOC Savings Per Patient  $ 18,336 USD Total SOC Savings for All Patients $6,600,960 USD Total % of SOC Savings  16.8%
Challenges ,[object Object],[object Object],[object Object]
Why it Works in Oncology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Trachtenberg surg onc risk icosna
Trachtenberg surg onc risk icosna Trachtenberg surg onc risk icosna
Trachtenberg surg onc risk icosna directoricos
 
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...Health Sciences North | Horizon Santé Nord
 
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...Cancer Institute NSW
 
Universal access to virtual colonoscopy may be on the horizon
Universal access to virtual colonoscopy may be on the horizonUniversal access to virtual colonoscopy may be on the horizon
Universal access to virtual colonoscopy may be on the horizonYael Waknine
 
Call on Congress 2014 John Marshall, Treatment
Call on Congress 2014 John Marshall, TreatmentCall on Congress 2014 John Marshall, Treatment
Call on Congress 2014 John Marshall, TreatmentFight Colorectal Cancer
 
Designed this online educational booklet for Association of Community Cancer ...
Designed this online educational booklet for Association of Community Cancer ...Designed this online educational booklet for Association of Community Cancer ...
Designed this online educational booklet for Association of Community Cancer ...Vickie Spindler
 
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?Canadian Cancer Survivor Network
 
EPAD 2017 - James N'Dow
EPAD 2017 - James N'DowEPAD 2017 - James N'Dow
EPAD 2017 - James N'DowMarc van Gurp
 
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...European School of Oncology
 
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
 
Asra defining value may 2015
Asra defining value may 2015Asra defining value may 2015
Asra defining value may 2015Colin McCartney
 
The experience of survival following Blood and Marrow Transplant in NSW, Aust...
The experience of survival following Blood and Marrow Transplant in NSW, Aust...The experience of survival following Blood and Marrow Transplant in NSW, Aust...
The experience of survival following Blood and Marrow Transplant in NSW, Aust...Cancer Institute NSW
 

La actualidad más candente (20)

Trachtenberg surg onc risk icosna
Trachtenberg surg onc risk icosna Trachtenberg surg onc risk icosna
Trachtenberg surg onc risk icosna
 
Manzo_a2hc_aamas
Manzo_a2hc_aamasManzo_a2hc_aamas
Manzo_a2hc_aamas
 
Northeast Case for Action: Colorectal Cancer, Mr. Mark Hartman
Northeast Case for Action: Colorectal Cancer, Mr. Mark HartmanNortheast Case for Action: Colorectal Cancer, Mr. Mark Hartman
Northeast Case for Action: Colorectal Cancer, Mr. Mark Hartman
 
ppm_information
ppm_informationppm_information
ppm_information
 
Rehab a.o'rourke
Rehab a.o'rourkeRehab a.o'rourke
Rehab a.o'rourke
 
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
 
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...
Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...
 
Universal access to virtual colonoscopy may be on the horizon
Universal access to virtual colonoscopy may be on the horizonUniversal access to virtual colonoscopy may be on the horizon
Universal access to virtual colonoscopy may be on the horizon
 
CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?
 
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
 
Call on Congress 2014 John Marshall, Treatment
Call on Congress 2014 John Marshall, TreatmentCall on Congress 2014 John Marshall, Treatment
Call on Congress 2014 John Marshall, Treatment
 
Designed this online educational booklet for Association of Community Cancer ...
Designed this online educational booklet for Association of Community Cancer ...Designed this online educational booklet for Association of Community Cancer ...
Designed this online educational booklet for Association of Community Cancer ...
 
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
 
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?
Canada's New Drug Pricing Rules: What are the Implications for Cancer Patients?
 
EPAD 2017 - James N'Dow
EPAD 2017 - James N'DowEPAD 2017 - James N'Dow
EPAD 2017 - James N'Dow
 
EPAD 2017 Ian Banks
EPAD 2017 Ian BanksEPAD 2017 Ian Banks
EPAD 2017 Ian Banks
 
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...
NY Prostate Cancer Conference - K. Touijer - Highlights of Day 2 breakout ses...
 
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Investor & Analyst Day 2015: Cologuard Expansion (2/8)
Investor & Analyst Day 2015: Cologuard Expansion (2/8)
 
Asra defining value may 2015
Asra defining value may 2015Asra defining value may 2015
Asra defining value may 2015
 
The experience of survival following Blood and Marrow Transplant in NSW, Aust...
The experience of survival following Blood and Marrow Transplant in NSW, Aust...The experience of survival following Blood and Marrow Transplant in NSW, Aust...
The experience of survival following Blood and Marrow Transplant in NSW, Aust...
 

Destacado

Investigator Grants
Investigator GrantsInvestigator Grants
Investigator GrantsTTC, llc
 
The State of Clinical Development - Globalization
The State of Clinical Development - GlobalizationThe State of Clinical Development - Globalization
The State of Clinical Development - GlobalizationTTC, llc
 
Emerging Regions - Alan Braverman
Emerging Regions - Alan BravermanEmerging Regions - Alan Braverman
Emerging Regions - Alan BravermanTTC, llc
 
Clinical Trial Costs in Emerging Geographies - Stephen Porter
Clinical Trial Costs in Emerging Geographies - Stephen PorterClinical Trial Costs in Emerging Geographies - Stephen Porter
Clinical Trial Costs in Emerging Geographies - Stephen PorterTTC, llc
 
SOC & Research BIlling Compliance
SOC & Research BIlling ComplianceSOC & Research BIlling Compliance
SOC & Research BIlling ComplianceTTC, llc
 
Compliance and FMV - Seth Whitelaw
Compliance and FMV - Seth WhitelawCompliance and FMV - Seth Whitelaw
Compliance and FMV - Seth WhitelawTTC, llc
 

Destacado (6)

Investigator Grants
Investigator GrantsInvestigator Grants
Investigator Grants
 
The State of Clinical Development - Globalization
The State of Clinical Development - GlobalizationThe State of Clinical Development - Globalization
The State of Clinical Development - Globalization
 
Emerging Regions - Alan Braverman
Emerging Regions - Alan BravermanEmerging Regions - Alan Braverman
Emerging Regions - Alan Braverman
 
Clinical Trial Costs in Emerging Geographies - Stephen Porter
Clinical Trial Costs in Emerging Geographies - Stephen PorterClinical Trial Costs in Emerging Geographies - Stephen Porter
Clinical Trial Costs in Emerging Geographies - Stephen Porter
 
SOC & Research BIlling Compliance
SOC & Research BIlling ComplianceSOC & Research BIlling Compliance
SOC & Research BIlling Compliance
 
Compliance and FMV - Seth Whitelaw
Compliance and FMV - Seth WhitelawCompliance and FMV - Seth Whitelaw
Compliance and FMV - Seth Whitelaw
 

Similar a Standard of Care - Donna Beardsworth

Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Office of Health Economics
 
2017 01 04 corporate presentation
2017 01 04 corporate presentation2017 01 04 corporate presentation
2017 01 04 corporate presentationKristine Mechem
 
FLAACOs 2014 Conference - Cancer Care in an ACO Landscape
FLAACOs 2014 Conference - Cancer Care in an ACO LandscapeFLAACOs 2014 Conference - Cancer Care in an ACO Landscape
FLAACOs 2014 Conference - Cancer Care in an ACO LandscapeMARCYINC
 
Precision Oncology adoption: The future is now
Precision Oncology adoption: The future is nowPrecision Oncology adoption: The future is now
Precision Oncology adoption: The future is nowaccenture
 
Part II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of RecurrencePart II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of Recurrencebkling
 
Rapid review of current service provision following cancer treatment
Rapid review of current service provision following cancer treatmentRapid review of current service provision following cancer treatment
Rapid review of current service provision following cancer treatmentNHS Improvement
 
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_WhitepaperUlrich Neumann, FRSA
 
Exact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
 
myeloma blocks, estrategias de tratamiento
myeloma blocks, estrategias de tratamientomyeloma blocks, estrategias de tratamiento
myeloma blocks, estrategias de tratamientoAlirioAnguloQuintero
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Andrew Aijian
 
Closing the loop_on_referral_management_processes_circo
Closing the loop_on_referral_management_processes_circoClosing the loop_on_referral_management_processes_circo
Closing the loop_on_referral_management_processes_circoAmy Stiner, RN, MBA, MPA
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General InternistLanceCatedral
 
Patterns of adoption and use of a web-based decision support system for CVD r...
Patterns of adoption and use of a web-based decision support system for CVD r...Patterns of adoption and use of a web-based decision support system for CVD r...
Patterns of adoption and use of a web-based decision support system for CVD r...Health Informatics New Zealand
 
Panel on Access
Panel on AccessPanel on Access
Panel on Accessflasco_org
 
Implementation science tailored to precision prevention
Implementation science tailored to precision preventionImplementation science tailored to precision prevention
Implementation science tailored to precision preventionGraham Colditz
 

Similar a Standard of Care - Donna Beardsworth (20)

Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
 
2017 01 04 corporate presentation
2017 01 04 corporate presentation2017 01 04 corporate presentation
2017 01 04 corporate presentation
 
FLAACOs 2014 Conference - Cancer Care in an ACO Landscape
FLAACOs 2014 Conference - Cancer Care in an ACO LandscapeFLAACOs 2014 Conference - Cancer Care in an ACO Landscape
FLAACOs 2014 Conference - Cancer Care in an ACO Landscape
 
Precision Oncology adoption: The future is now
Precision Oncology adoption: The future is nowPrecision Oncology adoption: The future is now
Precision Oncology adoption: The future is now
 
Setting Up for Survivorship Success
Setting Up for Survivorship SuccessSetting Up for Survivorship Success
Setting Up for Survivorship Success
 
Part II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of RecurrencePart II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of Recurrence
 
Rapid review of current service provision following cancer treatment
Rapid review of current service provision following cancer treatmentRapid review of current service provision following cancer treatment
Rapid review of current service provision following cancer treatment
 
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
 
Clorox Report
Clorox ReportClorox Report
Clorox Report
 
Exact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences Company Presentation Baird Healthcare Conference
Exact Sciences Company Presentation Baird Healthcare Conference
 
myeloma blocks, estrategias de tratamiento
myeloma blocks, estrategias de tratamientomyeloma blocks, estrategias de tratamiento
myeloma blocks, estrategias de tratamiento
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
 
Closing the loop_on_referral_management_processes_circo
Closing the loop_on_referral_management_processes_circoClosing the loop_on_referral_management_processes_circo
Closing the loop_on_referral_management_processes_circo
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General Internist
 
Patterns of adoption and use of a web-based decision support system for CVD r...
Patterns of adoption and use of a web-based decision support system for CVD r...Patterns of adoption and use of a web-based decision support system for CVD r...
Patterns of adoption and use of a web-based decision support system for CVD r...
 
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
 
American Journal of Anesthesia & Clinical Research
American Journal of Anesthesia & Clinical ResearchAmerican Journal of Anesthesia & Clinical Research
American Journal of Anesthesia & Clinical Research
 
Panel on Access
Panel on AccessPanel on Access
Panel on Access
 
Implementation science tailored to precision prevention
Implementation science tailored to precision preventionImplementation science tailored to precision prevention
Implementation science tailored to precision prevention
 
Oncology Treatment Guidelines : The Rules and Rationale
Oncology  Treatment Guidelines :The Rules and RationaleOncology  Treatment Guidelines :The Rules and Rationale
Oncology Treatment Guidelines : The Rules and Rationale
 

Más de TTC, llc

Clinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaClinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaTTC, llc
 
Observational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary ConsiderationsObservational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary ConsiderationsTTC, llc
 
Late Phase Study Planning and Budgeting
Late Phase Study Planning and BudgetingLate Phase Study Planning and Budgeting
Late Phase Study Planning and BudgetingTTC, llc
 
Annual State of Clinical Development Costs
Annual State of Clinical Development CostsAnnual State of Clinical Development Costs
Annual State of Clinical Development CostsTTC, llc
 
Future Challenges for Big Pharma
Future Challenges for Big PharmaFuture Challenges for Big Pharma
Future Challenges for Big PharmaTTC, llc
 
Working with Countries that are Difficult to Negotiate with
Working with Countries that are Difficult to Negotiate withWorking with Countries that are Difficult to Negotiate with
Working with Countries that are Difficult to Negotiate withTTC, llc
 
Investigator-Initiated Studies: Two Stories from the NIH
Investigator-Initiated Studies: Two Stories from the NIHInvestigator-Initiated Studies: Two Stories from the NIH
Investigator-Initiated Studies: Two Stories from the NIHTTC, llc
 
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...TTC, llc
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
 
Compliance and FMV - Karen Lowney
Compliance and FMV - Karen LowneyCompliance and FMV - Karen Lowney
Compliance and FMV - Karen LowneyTTC, llc
 
Effective Global Site Budgeting and Cost Management - Natalie Gosciminski
Effective Global Site Budgeting and Cost Management - Natalie GosciminskiEffective Global Site Budgeting and Cost Management - Natalie Gosciminski
Effective Global Site Budgeting and Cost Management - Natalie GosciminskiTTC, llc
 
Effective Global Site Budgeting and Cost Management - Forrest Swope
Effective Global Site Budgeting and Cost Management - Forrest SwopeEffective Global Site Budgeting and Cost Management - Forrest Swope
Effective Global Site Budgeting and Cost Management - Forrest SwopeTTC, llc
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
 
Payment Practices, FMV, and Study Performance - Harold Glass
Payment Practices, FMV, and Study Performance - Harold GlassPayment Practices, FMV, and Study Performance - Harold Glass
Payment Practices, FMV, and Study Performance - Harold GlassTTC, llc
 
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat AudetR&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat AudetTTC, llc
 
Two Worlds - Larry Poli
Two Worlds - Larry PoliTwo Worlds - Larry Poli
Two Worlds - Larry PoliTTC, llc
 
Effective Global Site Budgeting and Cost Management - Holly Squires
Effective Global Site Budgeting and Cost Management  - Holly SquiresEffective Global Site Budgeting and Cost Management  - Holly Squires
Effective Global Site Budgeting and Cost Management - Holly SquiresTTC, llc
 
Standard of Care - Ying Jiang
Standard of Care - Ying JiangStandard of Care - Ying Jiang
Standard of Care - Ying JiangTTC, llc
 

Más de TTC, llc (18)

Clinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaClinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharma
 
Observational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary ConsiderationsObservational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary Considerations
 
Late Phase Study Planning and Budgeting
Late Phase Study Planning and BudgetingLate Phase Study Planning and Budgeting
Late Phase Study Planning and Budgeting
 
Annual State of Clinical Development Costs
Annual State of Clinical Development CostsAnnual State of Clinical Development Costs
Annual State of Clinical Development Costs
 
Future Challenges for Big Pharma
Future Challenges for Big PharmaFuture Challenges for Big Pharma
Future Challenges for Big Pharma
 
Working with Countries that are Difficult to Negotiate with
Working with Countries that are Difficult to Negotiate withWorking with Countries that are Difficult to Negotiate with
Working with Countries that are Difficult to Negotiate with
 
Investigator-Initiated Studies: Two Stories from the NIH
Investigator-Initiated Studies: Two Stories from the NIHInvestigator-Initiated Studies: Two Stories from the NIH
Investigator-Initiated Studies: Two Stories from the NIH
 
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...
Phase IIIB & IV Studies Reflect the Evolution of Industry Needs & Market Real...
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
 
Compliance and FMV - Karen Lowney
Compliance and FMV - Karen LowneyCompliance and FMV - Karen Lowney
Compliance and FMV - Karen Lowney
 
Effective Global Site Budgeting and Cost Management - Natalie Gosciminski
Effective Global Site Budgeting and Cost Management - Natalie GosciminskiEffective Global Site Budgeting and Cost Management - Natalie Gosciminski
Effective Global Site Budgeting and Cost Management - Natalie Gosciminski
 
Effective Global Site Budgeting and Cost Management - Forrest Swope
Effective Global Site Budgeting and Cost Management - Forrest SwopeEffective Global Site Budgeting and Cost Management - Forrest Swope
Effective Global Site Budgeting and Cost Management - Forrest Swope
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
 
Payment Practices, FMV, and Study Performance - Harold Glass
Payment Practices, FMV, and Study Performance - Harold GlassPayment Practices, FMV, and Study Performance - Harold Glass
Payment Practices, FMV, and Study Performance - Harold Glass
 
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat AudetR&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
 
Two Worlds - Larry Poli
Two Worlds - Larry PoliTwo Worlds - Larry Poli
Two Worlds - Larry Poli
 
Effective Global Site Budgeting and Cost Management - Holly Squires
Effective Global Site Budgeting and Cost Management  - Holly SquiresEffective Global Site Budgeting and Cost Management  - Holly Squires
Effective Global Site Budgeting and Cost Management - Holly Squires
 
Standard of Care - Ying Jiang
Standard of Care - Ying JiangStandard of Care - Ying Jiang
Standard of Care - Ying Jiang
 

Standard of Care - Donna Beardsworth

  • 1. Standard Of Care Costs in Clinical Trials An Oncology-Focused CRO Perspective Presented by: Donna Beardsworth Founder
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 14. SOC Analysis – Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Leukemia Single Patient Duration 36 Months Number of Visits 34 Number of Patients 22 Number of Procedures 42 Number of SOC Procedures 34 Number of Expensive SOC Procedures 2 Total Cost for Procedures Per Patient before SOC $52,264 USD Total Cost for Procedures Per Patient after SOC $ 34,662 USD Total SOC Savings Per Patient $ 17,602 USD Total SOC Savings for All Patients $ 387, 244 USD Total % of SOC Savings 34 %
  • 15. SOC Analysis – Ovarian Cancer Single Patient Duration 89 Weeks Number of Visits 163 Number of Patients 360 Number of Procedures 18 Number of SOC Procedures 12 Number of Expensive Procedures 2 Total Cost for Procedures Per Patient before SOC $ 109,423 USD Total Cost for Procedures Per Patient after SOC $91,087 USD Total SOC Savings Per Patient $ 18,336 USD Total SOC Savings for All Patients $6,600,960 USD Total % of SOC Savings 16.8%
  • 16.
  • 17.

Notas del editor

  1. We have actually conducted trials or prepared regulatory documents for each of these indications.